SCHEMBL17023886

SCHEMBL17023886

c1ccc(-c2nc(-c3cnc(-c4nc(-c5ccccc5)n5ccccc45)cn3)c3ccccn23)cc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.51
MEN1 O00255 5/20 0.51
POLB P06746 2/20 0.51
HPGD P15428 2/20 0.51
GAA P10253 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
ALDH1A1 P00352 7/20 0.47
KDM4E B2RXH2 6/20 0.47
MAPT P10636 5/20 0.47
CHEK1 O14757 1/20 0.47
LIMK1 P53667 1/20 0.47
MAPK14 Q16539 1/20 0.47
TDP1 Q9NUW8 1/20 0.47
MAPK1 P28482 3/20 0.47
L3MBTL1 Q9Y468 2/20 0.47
SMN1; SMN2 Q16637 1/20 0.47
HIF1A Q16665 4/20 0.46
EPAS1 Q99814 4/20 0.46
LMNA P02545 1/20 0.40
RAD51 Q06609 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13325874 0.84 KMT2A (0.67) KMT2AMEN1POLBHPGDGAA
SCHEMBL24097052 0.84 GAA (0.49) KMT2AMEN1POLBHPGDGAA
SCHEMBL17023890 0.83 MEN1 (0.65) KMT2AMEN1POLBHPGDGAA
SCHEMBL17023902 0.83 GAA (0.40) KMT2AMEN1POLBHPGDGAA
SCHEMBL17023903 0.81 HPGD (0.55) KMT2AMEN1POLBHPGDGAA
SCHEMBL17023878 0.81 KMT2A (0.55) KMT2AMEN1POLBHPGDGAA
SCHEMBL17023874 0.81 KMT2A (0.59) KMT2AMEN1POLBHPGDGAA
SCHEMBL17023905 0.81 BRD4 (0.43) KMT2AMEN1POLBHPGDGAA
SCHEMBL38659326 0.81 GAA (0.52) KMT2AMEN1POLBHPGDGAA
SCHEMBL17023891 0.80 KMT2A (0.57) KMT2AMEN1POLBHPGDGAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10847726-B2 Imidizo derivatives THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) 2020-11-24 US disclosed
US-10847726-B2 Imidizo derivatives THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY (US) 2020-11-24 US disclosed
US-20190131538-A1 IMIDIZO DERIVATIVES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY 2019-05-02 US disclosed
US-20190131538-A1 IMIDIZO DERIVATIVES THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE ARMY 2019-05-02 US disclosed
US-20150243896-A1 IMIDAZO DERIVATIVES ARMY, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE 2015-08-27 US disclosed
US-20150243896-A1 IMIDAZO DERIVATIVES ARMY, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE 2015-08-27 US disclosed
US-20150243896-A1 IMIDAZO DERIVATIVES ARMY, THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF THE 2015-08-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190131538-A1 IMIDIZO DERIVATIVES IKZF1, IKZF3, IKZF2 KMT2A 1089/4885MEN1 3752/4885POLB 4046/4885
US-10847726-B2 Imidizo derivatives IKZF1, IKZF3, IKZF2 KMT2A 1089/4885MEN1 3752/4885POLB 4046/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.